Disparate Locations of the 52- and 60-kDa Ro/SS-A Antigens in Cultured Human Keratinocytes

Jennifer Anne Yell, Lixiang Wang, Hongliang Yin, and Daniel P. McCauliffe Department of Dermatology, University of North Carolina, Chapel Hill, NC, U.S.A.

Anti-52- and anti-60-kDa Ro/SS-A (Ro) autoantibodies are produced by most patients with subacute cutaneous lupus erythematosus and neonatal lupus erythematosus and are thought to be pathogenic in these two disorders. To learn more about the epidermal antigens targeted by Ro autoantibodies, a panel of anti-52 and anti-60-kDa Ro antibodies was purified from human autoimmune sera and rabbit antisera and then used to: (i) determine the expression and location of the Ro antigens in human keratinocytes; (ii) clarify discrepancies in previous localization studies; and (iii) verify the existence of Ro autoantibodies that cross-react with the 52- and 60kDa Ro antigens, as previously reported.

By immunoblot analysis these antibodies demonstrate that 52- and 60-kDa Ro proteins are expressed in normal human skin and cultured keratinocytes. By indirect immunofluorescence studies with cultured human cells, the anti-52-kDa Ro antibodies produce fine granular cytoplasmic fluorescence and less in-

A

nti-52- and anti-60-kDa Ro/SS-A (Ro) autoantibodies are produced by the vast majority of patients with subacute cutaneous lupus erythematosus and neonatal lupus erythematosus (McCauliffe *et al*, 1994). Although there is substantial evidence that

these autoantibodies are pathogenic in these two diseases (Lee et al, 1989; McCauliffe, 1995), the cellular function and location of their target antigens have remained controversial. Multiple studies have characterized the cellular location of Ro antigens by immunofluorescence techniques but with discrepant results. These discrepancies have arisen in part from differences in fixation techniques (Harmon et al, 1984; Peek et al, 1993), the use of non-human substrates (Harmon et al, 1984), and the utilization of human Ro autoimmune sera of varying specificities (Hendrick et al, 1981; Maddison et al, 1981; Harmon et al, 1984; Elenitsas et al, 1986; Lopez-Robles et al, 1986; Miyagawa et al, 1988). Recent studies, with standard fixation methods, human substrate, and more specific

Reprint requests to: D.P. McCauliffe, Suite 3100 Thurston Building, Department of Dermatology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599-7287.

Abbreviations: Ro autoantibody, anti-52- and anti-60-kDa Ro/SS-A autoantibody.

tense nuclear fluorescence, with apparent nucleolar sparing. The anti-60-kDa Ro autoantibodies produce weak cytoplasmic fluorescence and intense coarse granular nuclear fluorescence with apparent nucleolar sparing. We found distinct differences in the intracellular localization of the 52- and 60-kDa Ro autoantigens. This difference suggests that the 52and 60-kDa Ro antigens may have independent cellular functions. Finding 60-kDa Ro antigen predominantly in the nucleus challenges the notion that the majority of the intracellular 60-kDa Ro antigen is complexed with the cytoplasmic hY RNA. Additionally, our failure to find a cross-reactive epitope on these two proteins indicates that the 52-kDa Ro antigen is probably a true immunogen and not merely a protein that cross-reacts with anti-60-kDa Ro autoantibodies, as others have suggested. Key words: lupus/skin/immunofluorescence. J Invest Dermatol 107:622-626, 1996

Ro antibodies, however, have also produced discrepant results (Bachmann *et al*, 1986; Ben-Chetrit *et al*, 1988; Slobbe *et al*, 1991; Peek *et al*, 1993; Casciola-Rosen *et al*, 1994; Kelekar *et al*, 1994; Peek *et al*, 1994). The interpretations of these data are even less certain because it has been reported that some Ro autoantibodies cross-react with the 52- and 60-kDa Ro proteins (Itoh *et al*, 1992).

Our aims in this work were to determine the expression and localization of 52- and 60-kDa Ro antigens in human keratinocytes. We also hoped to clarify the discrepancies reported in previous localization studies by using a panel of anti–52- and anti–60-kDa Ro-specific antibodies, and to determine whether previous inconsistencies may have resulted from cross-reacting antibodies.

MATERIALS AND METHODS

Isolation of 52- and 60-kDa Ro-Encoding Clones cDNA clones that encode the 52- and 60-kDa Ro antigens were isolated and used to make recombinant glutathione S-transferase Ro fusion proteins, as previously described (McCauliffe *et al*, 1994).

Rabbit Immunization New Zealand white rabbits were immunized with agarose-linked recombinant 52- and 60-kDa fusion proteins according to a well established protocol (Oettinger *et al*, 1992).

Antibody Purification

Human and Rabbit Anti-Recombinant 52- and 60-kDa Ro Antibodies Ro fusion proteins were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis and then transferred electrophoretically to polyvinylidine difluoride paper (Immobilon-P, Millipore Corp, Bedford, MA) with a semi-dry transfer unit (Semi-phor TE70, Hoefer Scientific Instruments, San

0022-202X/96/\$10.50 · Copyright © 1996 by The Society for Investigative Dermatology, Inc.

Manuscript received February 20, 1996; revised May 28, 1996; accepted for publication June 7, 1996.

Dr. Yell is now at the Department of Dermatology, Leigh Infirmary, Leigh, U.K.

Francisco, CA). The paper was then blocked with Blotto (Harlowe and Lane, 1988) for several hours, incubated with human Ro autoimmune sera or rabbit anti-sera overnight at 4°C, and then washed three times with a large volume of $1 \times$ phosphate-buffered saline (PBS) at room temperature. The bound antibodies were stripped from the polyvinylidine diffuoride paper with 0.2 M glycine (pH 2.8) and immediately equilibrated to pH 8.0, with 1 M Tris, pH 9.5.

Human Anti-Native 60-kDa Ro Antibodies Twenty-four wells of a 96-well microtiter plate were coated with purified native bovine Ro (Immunovision, Springdale, AK) diluted to 8 U per ml in coating buffer (32 mM Na₂CO₃ and 68 mM NaHCO₃). These were incubated overnight at 4°C, blocked for 1 h (0.25% bovine serum albumin and 0.1% goat γ -globulin in 1× PBS), and incubated with a 1:5,000 dilution of high titer anti-native 60-kDa Ro containing autoimmune serum for 1 h. After two washes, the bound antibodies were stripped from each well with 0.2 M glycine, pH 2.8, for 5 min, and the pH was immediately equilibrated to pH 8.0, with 1 M Tris (hydroxymethyl)-aminomethane, pH 9.5. The antibodies from each well were pooled and concentrated (Spin-X UF concentrator, Costar, Cambridge, MA).

Enzyme-Linked Immunosorbent Assay (ELISA) Purified antibodies were tested against several recombinant proteins by ELISA, as previously described (McCauliffe *et al*, 1994).

Cell Extract Preparation A human skin extract was prepared from a freshly isolated plastic surgery specimen. The dermis was separated from the epidermis with 1 M NaCl, as previously described (Woodley *et al*, 1984). The epidermis was then snap-frozen in liquid nitrogen and pulverized. The pulverized epidermis was suspended in lysis buffer (50 mM NaCl, 0.3% Nonidet P-40, 10 mM dithiothreitol, 15 mM ethylenediamine tetraacetic acid) containing protease inhibitors [1.4 mM phenylmethanesulfonyl fluoride, pepstatin (2.5 μ g/ml), leupeptin (0.5 μ g/ml), and aprotinin (0.4 μ g/ml)], and the supernatant fraction was collected by centrifugation. Wil-2 cell (ATCC CRL 8885) and cultured human keratinocyte extracts were similarly made by suspending ×10⁶⁻⁷ cells in 1 ml of lysis buffer followed by sonication with three 20-s bursts.

Immunoblot Analysis Immunoblot analysis was performed on the human skin, cultured keratinocytes, and Wil-2 cell extracts as previously described (McCauliffe *et al*, 1994). The Wil-2 human lymphoblastoid cell line served as a positive control as this cell line has previously been shown to express both the 52- and 60-kDa Ro mRNA (McCauliffe *et al*, 1994).

Keratinocyte Culture Neonatal foreskins were stored in Dulbecco's modified Eagle's medium-high glucose, with 1 mM sodium pyruvate, 2% fetal bovine serum, 5 μ g ketoconazole per ml, 100 μ g chloramphenicol per ml, 100 U penicillin per ml, 100 μ g streptomycin per ml, 250 ng amphotericin B per ml, and 20 mM HEPES (pH 7.3), for less than 24 h. They were washed and trypsinized overnight at 4°C. The keratinocytes were resuspended in medium 154 with human keratinocyte growth supplement (Cascade Biologics, Inc, Portland, OR). Second passage keratinocytes were thawed and seeded onto eight-chamber Lab Tek slides (Nunc Inc., Naperville, IL). They were grown to 50% confluence.

Immunofluorescence The keratinocytes were fixed in 3% paraformaldehyde at 4°C for 15 min, followed by two brief washes with 1× PBS. They were permeabilized for 5 min with 0.1% Triton X in PBS, washed twice with 1× PBS, and then incubated for 1 h at 4°C with the purified Ro antibodies. Following another two $1 \times$ PBS washes, goat anti-human IgG conjugated to Texas Red and/or goat anti-rabbit IgG conjugated to fluorescein isothiocyanate (Sigma, St. Louis, MO) was added for 30 min at 4°C. The slides were washed twice, the chambers were removed, and the slides were coverslipped with polyvinyl alcohol mounting media. The slides were viewed with a conventional epifluorescence microscope, followed by confocal microscopy. Two confocal microscope systems were used. Images were collected with a Bio-Rad MRC-600 laser scanning confocal microscope (Bio-Rad Ltd, Hemel Hempstead, Herts, U.K.) mounted onto a Nikon Diaphot inverted microscope, with a 100× objective and a pinhole setting of 3 to maximize optical sectioning, at 0.8-0.9 µm. A double dichroic mirror directed a 488- and/or 568-nm argon-krypton laser to the sample. Excitation light was attenuated with a 1% neutral density filter to minimize photobleaching. The other confocal system used was a Zeiss invert LSM 410 with software version 3.50 (Gottingen, Germany) with a pinhole of 20 and a similar neutral density filter. The contrast and brightness adjustments were maintained at constant levels for all experiments and controls. Each digital image was obtained with a laser exposure time of 8 s, averaged over 4 s, to reduce noise. Confocal images were processed with



Figure 1. Extracts from human epidermis (SE), cultured keratinocytes (KE), and Wil-2 cells (WE) express 52- and 60-kDa Ro proteins as demonstrated by immunoblot analysis. Each extract was subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis, transferred to polyvinylidine difluoride paper, and then incubated with a 1:25 dilution of Ro-negative autoimmune control sera (AS), purified human anti-60-2 antibodies (60), and human anti-52-2 antibodies purified from two different autoimmune sera (52 and 52').

Adobe Photoshop version 3.0 software and printed on an Epson Stylus color printer (Epson America, Inc., Torrance, CA).

RESULTS

Multiple Types of Anti-52- and Anti-60-kDa Ro Antibodies Were Purified Rabbit antibodies were purified against full length recombinant 52- and 60-kDa Ro proteins. Human autoantibodies were affinity purified against two different recombinant 52-kDa Ro fragments [52-1b (amino acids 1–98) and 52-2 (amino acids 138–340)] and two different recombinant 60-kDa Ro fragments [60-2 (amino acids 139–326) and 60-4 (amino acids 410– 538)]. Each of the four fragments had previously been shown to contain at least one major Ro epitope [52-2, 60-2, 60-4: (McCauliffe *et al*, 1994); 52-1b: personal unpublished observation). Human antibodies were also purified against the native 60-kDa Ro protein, which contains one or more epitopes not expressed by the recombinant Ro proteins (McCauliffe *et al*, 1994).

Cultured Keratinocytes and Human Epidermis Express the 52- and 60-kDa Ro Proteins The specificities of the purified antibodies were demonstrated by immunoblot (Fig 1) and ELISA (Fig 2). These antibodies identified appropriately sized proteins in keratinocyte extracts prepared from surgical and cultured specimens, indicating that both Ro proteins are expressed in normal human skin and in cultured human keratinocytes, respectively. Multiple protein fragments were labeled with the anti-52-kDa Ro antibodies. Whether these fragments represent protein degradation, different forms of the 52-kDa Ro protein, or cross-reactive proteins is uncertain. The smear-like nature of the fragments, with a greater proportion of smaller fragments in the skin extract preparation, which takes longer to prepare than the cultured keratinocyte and Wil-2 cell extracts, would suggest that these fragments arise from protein degradation.

None of the Purified Ro Autoantibodies React with Both 52- and 60-kDa Ro Proteins There was no convincing evidence of cross-reactivity between the anti-52- and anti-60-kDa Ro antibodies by immunoblot. Furthermore, the ELISA results of our entire panel of purified Ro antibodies failed to validate the existence of the previously described cross-reactive epitope shared by the 52- and 60-kDa Ro proteins (Itoh *et al*, 1992).

Disparate Locations of 52- and 60-kDa Ro Proteins in Cultured Keratinocytes The cellular locations of the 52- and 60-kDa Ro proteins were determined by conventional epifluorescence and scanning confocal microscopy, including Z-series. The human anti-52-1b and 52-2 autoantibodies stained the cytoplasm in a fine granular pattern, with similar nuclear staining that was most



Figure 2. Purified Ro antibodies were specific for either the 52- or the 60-kDa Ro protein as demonstrated by ELISA. (*a*) Purified human anti–52-1b, anti–52-2, rabbit antisera raised against whole recombinant 52-kDa Ro (rab anti–52), and a 1:100 dilution of normal sera (normal) were reacted with a panel of antigens. (*b*) Purified human anti–60-2, anti–60-4, anti-native 60-kDa Ro (anti–n60), and rabbit antisera raised against the full-length recombinant 60-kDa Ro (rab anti–60), were similarly tested. Purified antigens: n60, native 60-kDa Ro; whole 60, full-length recombinant 60-kDa Ro; (*ab* anti–60), were similarly tested. Purified antigens: n60, native 60-kDa Ro; whole 60, full-length recombinant 60-kDa Ro; 60-2, recombinant 60-2 fragment (amino acids 139–326); 60-4, recombinant 60-4 fragment (amino acids 410–538); whole 52, full-length recombinant 52-kDa Ro; 52-1, recombinant 52-1 fragment (amino acids 1–178); 52-2, recombinant 52-2 fragment (amino acids 138–340); La, native La/SS-B autoantigen; and GST, recombinant glutathione S-transferase, which was a component of each recombinant fusion protein in this antigen panel.

apparent in cells that had not yet reached confluence. Cells that had reached confluence often demonstrated minimal nuclear staining (Fig 3). Both the human anti-60-2 and 60-4 autoantibodies strongly stained the nucleus in a coarse granular pattern, with absent nucleolar and weak cytoplasmic staining (Fig 4). The human anti-native 60-kDa Ro autoantibodies stained the cells similarly. Differences in 52- and 60-kDa Ro localization were confirmed by double immunofluorescence utilizing purified human and rabbit anti-52- and anti-60-kDa Ro antibodies (Fig 5).

A similar analysis was performed on HEp-2 and HeLa cells, as several earlier studies did not detect differences in the locations of the 52- and 60-kDa Ro proteins in these cells (Ben-Chetrit *et al*, 1988; Slobbe *et al*, 1991; Peek *et al*, 1994). Cytoplasmic fluorescence was more pronounced with anti-52 than with anti-60-kDa Ro antibodies in these two epithelial cell lines. More nuclear fluorescence, however, was detected with anti-52-kDa Ro antibodies in HEp-2 and HeLa cells than in keratinocytes. This difference was most striking in cells that had reached confluence (Figs 3, 6).

DISCUSSION

Localization Studies Reveal Disparate Locations of the 52and 60-kDa Ro Antigens Ro cellular localization studies have produced inconsistent results for many years. Recent localization studies have found predominantly nuclear and minor cytoplasmic localization of both the 52- and 60-kDa Ro antigens in HEp-2 and HeLa cells (Ben-Chetrit *et al*, 1988; Slobbe *et al*, 1991; Casciola-Rosen *et al*, 1994; Peek *et al*, 1994). Another study, however, found predominantly cytoplasmic localization of 60-kDa Ro and mostly nuclear localization of 52-kDa Ro in HeLa and HEp-2 cells



Figure 3. Confocal laser microphotographs reveal both nuclear and cytoplasmic localization of 52-kDa Ro. Immunofluorescence of cultured human keratinocytes with purified human anti–52-1b antibodies (*two panels on the left*) and anti–52-2 antibodies (*two panels on the right*). The *two uppermost panels* depict nonconfluent cells, and the *two lowermost panels* show cells that have reached confluence. Scale bar, 25 µm.



Figure 4. Confocal laser microphotographs reveal predominantly nuclear localization of 60-kDa Ro. Immunofluorescence of cultured human keratinocytes with purified human anti–60-2, anti–60-4, anti-native bovine 60-kDa Ro, and a 1:100 dilution of normal serum, as depicted. *Scale bar*, 25 μ m.



Figure 5. Confocal laser microphotographs of the double-immunofluorescent localizations of 52- and 60-kDa Ro confirm disparate locations of the 52- and 60-kDa Ro proteins in confluent keratinocytes. Double immunofluorescence of cultured human keratinocytes with (A) purified rabbit anti-60 kDa Ro antibodies (detected with fluorescein isothiocyanate-conjugated goat anti-rabbit antibodies) seen as green fluorescence, and human anti-52-2 antibodies (detected with Texas Red-conjugated goat anti-human antibodies) seen as orange fluorescence; and (B) purified rabbit anti-52-kDa Ro antibodies (detected with fluorescein isothiocyanate-conjugated goat anti-rabbit antibodies) seen as green fluorescence and human anti-60-2 antibodies (detected with Texas Red-conjugated goat anti-human antibodies) seen as orange fluorescence. Scale bar, 25 μ m.

(Kelekar *et al*, 1994). Unfortunately most of these studies relied on a single monospecific autoimmune sera and/or antisera with anti-52 or anti-60-kDa Ro activity, and the specificity of these reagents was often not well defined. Monospecific anti-52-kDa Ro sera were defined by immunoblot analysis and may have contained anti-60-kDa Ro antibodies as this method does not detect all anti-60-kDa Ro antibodies (Boire *et al*, 1991).

Our immunofluorescence data are more convincing than any yet published because we used a panel of non-cross-reactive anti-52 and anti-60-kDa Ro- specific antibodies, all of which produced consistent yet disparate locations of the 52- and 60-kDa Ro antigens. Our predominantly nuclear localization of the 60-kDa Ro antigen is consistent with most of the earlier studies and a recent study that utilized monoclonal anti-60-kDa Ro antibodies (Veldhoven et al, 1995). We found, however, greater cytoplasmic localization of the 52-kDa Ro protein than did previous work. Most of the recent localization studies utilized "monospecific" 52-kDa Ro autoimmune sera (Ben-Chetrit et al, 1988; Slobbe et al, 1991; Casciola-Rosen et al, 1994) or partially purified rabbit antisera (Kelekar et al, 1994) that may have contained anti-native 60-kDa Ro or other autoantibodies that could produce nuclear fluorescence that overshadowed the cytoplasmic fluorescence generated by the anti-52-kDa Ro antibodies.

Overexpression of the 52-kDa Ro-encoding gene in HEp-2 and LTA-5 cells has demonstrated predominantly cytoplasmic localization of its protein product.¹ This same group had previously overexpressed the 60-kDa Ro protein and found predominantly nuclear localization (Keech *et al*, 1994).

We repeated our localization studies on HeLa and HEp-2 cells to make certain that our findings weren't unique to cultured keratinocytes. Our panel of anti-52- and anti-60-kDa Ro antibodies produced patterns of fluorescence in HeLa and HEp-2 cells similar to those in the cultured keratinocytes (Fig 6), but diminished amounts of 52-kDa Ro in the nuclei of confluent HEp-2 and HeLa cells, as had been shown in confluent keratinocytes, were not demonstrated. This difference suggests that the 52-kDa Ro's cellular distribution may change as a result of keratinocyte differenti-

¹ Keech C, Gordon T, McCluskey, J: Cytoplasmic localization of the 52 kDa Ro/SS-A autoantigen in transfected mammalian cells and cloning of a mouse homolog. *Arthritis Rheum* 37(suppl):S172, 1994 (abstr.).

ation induced by cell-cell contact, a change that may not occur in the immortalized HEp-2 and HeLa cells.

No Evidence That Ro Autoantibodies Cross-React with the 52- and 60-kDa Ro Molecules Itoh et al previously reported that a major denaturation-resistant epitope on the 52-kDa Ro protein is cross-reactive with Ro autoantibodies directed against an epitope expressed on the native 60-kDa Ro protein (Itoh et al, 1992). We have now shown that Ro autoantibodies purified against two different portions of the recombinant 52-kDa Ro (52-2 contains the previously described denaturation-resistant epitope), fail to react with the recombinant human 60-kDa Ro protein or the purified native bovine 60-kDa Ro protein (Fig 2). Likewise, autoantibodies purified from the native 60-kDa Ro protein and two different fragments of the recombinant human 60-kDa Ro protein failed to react with the recombinant 52-kDa protein and protein fragments (Fig 2). Whether the discrepancy between our data and that of Itoh et al resulted from differences in patient sera reactivities, source of Ro antigen, or methodology is uncertain. Other studies have also failed to reveal cross-reactivity of anti-52- and anti-60kDa Ro autoantibodies (Ben-Chetrit et al, 1988; Peek et al, 1993; Keech et al, 1994; St.Clair et al, 1994).

52- and 60-kDa Ro Proteins Are Expressed in Cultured Human Keratinocytes and in Human Epidermis We have demonstrated that keratinocytes harvested directly from adult skin or from culture express both the 52- and 60-kDa Ro antigens. Our results differ from an earlier report that found no difference in the localization of 52- and 60-kDa Ro antigens in unprovoked cultured keratinocytes (Casciola-Rosen *et al*, 1994). This previous study used an anti–52-kDa Ro monospecific serum defined by immunoblot results, which may have contained anti–60-kDa Ro antibodies that masked the true localization of the 52-kDa Ro, as immunoblot analysis does not detect all anti-60 kDa Ro antibodies (Boire *et al*, 1991).

Previous studies have supported the hypothesis that ultraviolet B irradiation induces Ro antigens to translocate to the keratinocyte membrane where they might be bound by Ro autoantibodies and cause skin injury in neonatal lupus erythematosus and subacute cutaneous lupus erythematosus (LeFeber *et al*, 1984; Furukawa *et al*, 1990; Golan *et al*, 1992; Jones, 1992; Furukawa *et al*, 1994). Unfortunately, because these studies used poorly characterized monospecific Ro sera, it remains to be determined whether the 52-kDa Ro, 60-kDa Ro, or both proteins are so translocated. With our panel of Ro autoantibodies, we have found no evidence of 52-or 60-kDa Ro antigen expression on the surface of cultured keratinocytes before or 24 h after terrestrial-strength doses of



Figure 6. Epiluminescence microphotographs of the immunofluorescent localization of 52 and 60 kDa Ro antigens in HeLa (two uppermost panels) and HEp-2 cells (two lowermost panels) with anti-60and anti-52-kDa Ro antibodies as indicated. Scale bar, 25 μ m.

We have demonstrated by immunoblot analysis that normal human epidermis expresses both the 52- and 60-kDa Ro antigens (Fig 1). We have been unsuccessful, however, in localizing the 52and 60-kDa Ro antigens in human skin biopsies by indirect immunofluorescence, despite having used different techniques on sections obtained from several donors (data not shown). We speculate that our inability to localize the antigens may be related to technical matters, but it is also possible that our skin biopsies came from individuals that produce low amounts of Ro antigen, e.g., Niimi *et al* (1995) have recently reported finding up to a 2,000-fold difference in 60-kDa Ro skin expression among individuals. We have not noted such a difference in the level of 52- and 60-kDa Ro antigen expression in cultured keratinocytes harvested from several donors.

It Is Likely That the Majority of Intracellular 60-kDa Ro Is Not Complexed with hY RNA The functions of the 52- and 60-kDa Ro proteins remain unknown. There are convincing data that the 60-kDa Ro protein associates with cellular hY RNA as a ribonucleoprotein complex. It has been argued that the 52-kDa Ro protein is also a component of this complex (Peek et al, 1993), but others dispute this claim (Slobbe et al, 1992; Kelekar et al, 1994). Our findings indicate that the majority of 52- and 60-kDa Ro proteins are not complexed together. We would, however, have to add that given some similarities in distribution, it is possible that some 52- and 60-kDa Ro molecules are components of the same ribonucleoprotein particles. Cell fractionation methods and hY RNA and Ro protein injection studies have demonstrated that the Ro ribonucleoprotein complex is located predominately in the cytoplasm (Peek et al, 1993, 1994). Our localization of the 60-kDa Ro protein predominantly to the nucleus would therefore indicate that only a minority of the total cellular 60-kDa Ro protein is complexed with cytoplasmic hY RNA. Peek et al (1993) have reported that the majority of 60-kDa Ro is in fact located in the cytoplasm, but autoantibodies cannot detect it because of epitope masking when the protein is part of the Ro ribonucleoprotein particles. It is possible that our immunofluorescence methods of fixation and/or permeabilization may have failed to preserve and/or unmask epitopes on the cytoplasmic form of 60-kDa Ro. This is less likely, however, as we have used antibodies reactive with at least three different 60-kDa Ro epitopes, and other investigators, using different immunofluorescence techniques, have also found a predominantly nuclear distribution of the 60-kDa Ro antigen (Lopez-Robles et al, 1986; Ben-Chetrit et al, 1988; Casciola-Rosen et al, 1994; Peek et al, 1994; Veldhoven et al, 1995).

This work was supported by the National Institutes of Health Grant AR41445. Dr. Yell is an Arthritis and Rheumatism Council (United Kingdom) Copeman traveling fellow. We are grateful to Sam Tesfai for his technical assistance with confocal microscopy.

REFERENCES

- Bachmann M, Mayet WJ, Schroder HC, Pfeifer K, Meyer zum Buschenfelde KH, Muller WEG: Association of La and Ro antigens with intracellular structures in HEp-2 carcinoma cells. Proc Natl Acad Sci USA 83:7770–7774, 1986
- Ben-Chetrit E, Chan EKL, Sullivan KF, Tan EM: A 52-kD protein is a novel component of the SS-A/Ro antigenic particle. J Exp Med 167:1560-1571, 1988
- Boire G, Lopez-Longo F, LaPointe S, Menard HA: Sera from patients with autoimmune disease recognize conformational determinants on the 60-kd Ro/SS-A protein. Arthritis Rheum 34:722–730, 1991
- Casciola-Rosen LA, Anhalt G, Rosen A: Autoantigens targeted in systemic lupus erythematosus are clustered in two poulations of surface structures on apoptotic keratinocytes. J Exp Med 179:1317–1330, 1994

- Elenitsas R, Bair LWJ, Medsger TA, Deng J: Discordance of SSA/Ro and SSB/La cellular antigens in synchronized cells. J Invest Dermatol 87:504-509, 1986
- Furukawa F, Kanauchi H, Imamura S: Susceptibility to UVB light in cultured keratinocytes of cutaneous lupus erythematosus. Dematology 189:18-23, 1994
- Furukawa F, Kashihara-Sawami M, Lyons MB, Norris DA: Binding of antibodies to ENA SS-A/Ro and SS-B/La is induced on the surface of human keratinocytes by UVL: Implications for the pathogenesis of photosensitive cutaneous lupus. J Invest Dermatol 94:77–85, 1990
- Golan TD, Elkon KB, Gharavi AE, Krueger JG: Enhanced membrane binding of autoantibodies to cultured keratinocytes of systemic lupus erythematosus patients after ultraviolet B/ultraviolet A irradiation. J Clin Invest 90:1067–1076, 1992
- Harlowe E, Lane D: Immunoblotting. In: Antibodies A Laboratory Manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1988, chapter 12, pp 471–510
- Harmon CE, Deng J, Peebles CL, Tan EM: The importance of tissue substrate in the SS-A/Ro antigen-antibody system. Arthritis Rheum 27:166–173, 1984
- Hendrick JP, Wolin SL, Rinke J, Lerner MR, Steitz JA: Ro small cytoplasmic ribonucleoproteins are a subclass of La ribonucleoproteins: further characterization of the Ro and La small ribonucleoproteins from uninfected mammalian cells. *Mol Cell Biol* 1:1138–1149, 1981
- Itoh Y, Itoh K, Frank MB, Reichlin M: Autoantibodies to the Ro/SSA autoantigen are conformation dependent II: antibodies to the denatured form of 52 kD Ro/SSA are a cross reacting subset of antibodies to the native 60 kD Ro/SSA molecule. *Autoimmunity* 14:89–95, 1992
- Jones SK: Ultraviolet radiation (UVR) induces cell-surface Ro/SS-A antigen expression by human keratinocytes *in vitro*: a possible mechanism for UVR induction of cutaneous lupus lesions. Br J Dermatol 126:546-553, 1992
- Keech CL, McCluskey J, Gordon TP: Transfection and overexpression of the human 60-kDa Ro/SS-A autoantigen in HEp-2 cells. Clin Immunol Immunopathol 73: 146-151, 1994
- Kelekar A, Saitta MR, Keene JD: Molecular composition of Ro small ribonucleoprotein complexes in human cells: intracellular localization of the 60- and 52-kD proteins. J Clin Invest 93:1637–1644, 1994
- Lee LA, Gaither KK, Coulter SN, Norris DA, Harley JB: Pattern of cutaneous immunoglobulin G deposits in subacute cutaneous lupus erythematosus is reproduced by infusing purified anti-Ro(SSA) autoantibodies into human skingrafted mice. J Clin Invest 83:1556–1562, 1989
- LeFeber WP, Norris DA, Ryan SR, Huff JC, Lee LA, Kubo M, Boyce ST, Kotzin BL, Weston WL: Ultraviolet light induces binding of antibodies to selected nuclear antigens on cultured human keratinocytes. J Clin Invest 74:1545–1551, 1984
- Lopez-Robles E, Herrera-Esparza R, Avalos-Diaz E: Cellular localization of the Ro/SS-A antigen. Clin Rheumatol 5:33-38, 1986
- Maddison P. J., Provost T. T., Reichlin M: Serologic findings in patients with "ANA-negative" SLE. *Medicine* 60:87–94, 1981
- McCauliffe DP: Neonatal lupus erythematosus: a transplacentally acquired autoimmune disorder. Semin Dermatol 14:47–53, 1995
- McCauliffe DP, Yin H, Wang L, Lucas L: Autoimmune sera react with multiple epitopes on recombinant 52 and 60 kDa Ro(SSA) proteins. J Rheumatol 21:1073– 1080, 1994
- Miyagawa S, Okada N, Inagaki Y, Kitano Y, Ueki H, Sakamoto K, Steinberg ML: SSA/Ro antigen expression in simian virus 40-transformed human keratinocytes. J Invest Dermatol 90:342–345, 1988
- Niimi Y, Ioannides D, Buyon J, Bystryn JC: Heterogeneity in the expression of Ro and La antigens in human skin. Arthritis Rheum 38:1271–1276, 1995
- Oettinger HF, Pasqualini R, Bernfield M: Recombinant peptides as immunogens: A comparison of protocols for antisera production using the pGEX system. *BioTechniques* 12:544–549, 1992
- Peek R, Pruijm GJM, van der Kemp AJW, van Venrooij WJ: Subcellular distribution of Ro ribonucleoprotein complexes and their constituents. J Cell Sci 106:929– 935, 1993
- Peek R, van Venrooij WJ, Simons F, Pruijn G: The SS-A/SS-B autoantigenic complex: localization and assembly. *Clin Exp Rheumatol* 12(suppl 11):S15–S18, 1994
- Slobbe RL, Pluk W, van Venrooij WJ, Pruijn GJM: Ro ribonucleoprotein assembly in vitro: Identification of RNA-protein and protein-protein interactions. J Mol Biol 227:361–366, 1992
- Slobbe RL, Pruijn GJM, Damen WGM, Van Der Kemp JWCM, Van Venrooj WJ: Detection and occurrence of the 60- and 52-kD Ro (SS-A) antigens and of autoantibodies against these proteins. *Clin Exp Immunol* 86:99–105, 1991
- St.Clair EW, Burch, Jr., Saitta M: Specificity of autoantibodies for recombinant 60-kD and 52-kD Ro autoantigens. *Anhritis Rheum* 37:1373–1379, 1994
- Veldhoven CHA, Pruijn GJM, Meilof JF, Thijssen JPH, van der Kemp AWCM, van Venrooij WJ, Smeenk RJT: Characterization of murine monoclonal antibodies against 60-kD Ro/SS-A and La/SS-B autoantigens. *Clin Exp Immunol* 101:45–54, 1995
- Woodley DT, Briggaman RA, O'Keefe EJ, Inman AO, Queen LL, Gammon WR: Identification of the basement-membrane autoantigen in epidermolysis bullosa acquisita. N Engl J Med 310:1007–1013, 1984